News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Eli Lilly and Company, Merck KGaA Erbitux Fails to Stop Colon Cancer Before It Spreads
June 7, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Eli Lilly & Co. and Merck KGaA’s Erbitux, approved for advanced colon cancer, failed to slow tumors in a study designed to expand the medicine’s use to patients whose disease is in an earlier stage.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
Eli Lilly and Company
MORE ON THIS TOPIC
Cancer
Cogent Hits ‘Unprecedented’ Efficacy in Rare Stomach Cancer, Clearing Path to FDA
November 11, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Ionis’ Tryngolza ‘Game-Changing in Lowering Triglycerides, Cementing Case for FDA Filing
November 10, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Merck Builds Case for Cholesterol-Lowering Pill With Injectable-Like Efficacy
November 10, 2025
·
2 min read
·
Tristan Manalac
IgA nephropathy
Vera Builds ‘Compelling Profile’ for Atacicept in IgAN, Eyes Q4 Filing
November 7, 2025
·
2 min read
·
Tristan Manalac
